We are live on !
Find out more
Commodore Capital Portfolio holdings
AUM
$1.68B
Turnover
31.71%
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$59.6M
(+4.4%)
Cap. Flow
-$61.6M
Cap. Flow % of AUM
Cap. Flow %
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
62.23%
Holding
38
New
7
Increased
10
Reduced
8
Closed
5
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$51.6M |
| 2 |
Relay Therapeutics
RLAY
|
+$39.7M |
| 3 |
Cidara Therapeutics
CDTX
|
+$28.2M |
| 4 |
Kymera Therapeutics
KYMR
|
+$25.8M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$22.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$62.3M |
| 2 |
Merus
MRUS
|
+$44.6M |
| 3 |
Soleno Therapeutics
SLNO
|
+$40.4M |
| 4 |
Vera Therapeutics
VERA
|
+$39.6M |
| 5 |
Cogent Biosciences
COGT
|
+$36.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.44% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Merus
MRUS
| $185M | 13.09% |
3,525,000
-947,840
| -21% | -$44.6M |
2021 Q3
15 quarters
|
|
2
DELISTED
Nuvalent
NUVL
| $105M | 7.41% |
1,375,000
-480,000
| -26% | -$35.1M |
2022 Q4
10 quarters
|
|
|
3
Xenon Pharmaceuticals
XENE
$3.42B
| $94.7M | 6.68% |
3,025,000
+700,000
| +30% | +$22.8M |
2020 Q4
18 quarters
|
|
4
Enliven Therapeutics
ELVN
$3.04B
| $94.1M | 6.64% |
4,692,809
+17,809
| +0.4% | +$337K |
2022 Q4
10 quarters
|
|
5
Agios Pharmaceuticals
AGIO
$2.21B
| $77.3M | 5.46% |
2,325,000
+140,000
| +6% | +$4.24M |
2025 Q1
1 quarter
|
|
6
Celldex Therapeutics
CLDX
$2.3B
| $70.2M | 4.96% |
3,450,000
+250,000
| +8% | +$4.87M |
2025 Q1
1 quarter
|
|
7
Alkermes
ALKS
$7.32B
| $70.1M | 4.95% |
2,450,000
+500,000
| +26% | +$14.9M |
2024 Q2
4 quarters
|
|
8
Viridian Therapeutics
VRDN
$2.53B
| $68.2M | 4.81% |
4,875,000
+1,275,000
| +35% | +$17.3M |
2021 Q1
17 quarters
|
|
|
9
Protagonist Therapeutics
PTGX
$8.96B
| $59.4M | 4.19% |
+1,075,000
| New | +$51.6M |
2025 Q2
0 quarters
|
|
|
10
DELISTED
Cidara Therapeutics
CDTX
| $57.2M | 4.04% |
+1,175,000
| New | +$28.2M |
2025 Q2
0 quarters
|
|
11
Scholar Rock
SRRK
$5.05B
| $51.4M | 3.63% |
1,450,000
-295,000
| -17% | -$9.26M |
2024 Q4
2 quarters
|
|
|
12
DELISTED
Soleno Therapeutics
SLNO
| $51.1M | 3.61% |
610,000
-540,000
| -47% | -$40.4M |
2023 Q3
7 quarters
|
|
|
13
Relay Therapeutics
RLAY
$3.98B
| $46.2M | 3.26% |
+13,350,000
| New | +$39.7M |
2025 Q2
0 quarters
|
|
14
Nurix Therapeutics
NRIX
$2.77B
| $45M | 3.17% |
3,948,653
-30,254
| -0.8% | -$327K |
2024 Q3
3 quarters
|
|
|
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
| $43.3M | 3.06% |
3,298,289
+930,711
| +39% | +$11.8M |
2024 Q3
3 quarters
|
|
16
Pharvaris
PHVS
$2.21B
| $33.6M | 2.37% |
1,911,433
| – | – |
2023 Q4
6 quarters
|
|
|
17
Kymera Therapeutics
KYMR
$9.21B
| $32.7M | 2.31% |
+750,000
| New | +$25.8M |
2025 Q2
0 quarters
|
|
18
Definium Therapeutics
DFTX
$4.79B
| $32.4M | 2.29% |
5,000,000
+475,000
| +10% | +$3.12M |
2024 Q1
5 quarters
|
|
19
Spyre Therapeutics
SYRE
$8.44B
| $29.8M | 2.1% |
1,988,084
| – | – |
2023 Q2
8 quarters
|
|
20
Tyra Biosciences
TYRA
$1.41B
| $29.7M | 2.09% |
3,100,000
+2,150,000
| +226% | +$20.4M |
2025 Q1
1 quarter
|
|
|
21
Vera Therapeutics
VERA
$2.02B
| $18.8M | 1.33% |
800,000
-1,761,782
| -69% | -$39.6M |
2023 Q1
9 quarters
|
|
22
CytomX Therapeutics
CTMX
$506M
| $17.5M | 1.23% |
+7,692,300
| New | +$12.4M |
2025 Q2
0 quarters
|
|
|
23
Cogent Biosciences
COGT
$5.42B
| $16.6M | 1.17% |
2,311,164
-6,581,652
| -74% | -$36.5M |
2020 Q4
18 quarters
|
|
24
Oruka Therapeutics
ORKA
$5.31B
| $15.9M | 1.12% |
1,419,714
| – | – |
2024 Q2
4 quarters
|
|
25
Bright Minds Biosciences
DRUG
$518M
| $13.1M | 0.92% |
500,000
| – | – |
2024 Q4
2 quarters
|
|
Similar funds
SH
TP
IAIM
Commodore Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Commodore Capital held 38 positions worth $1.42B, up 4.4% from $1.36B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Commodore Capital withdrew a net $61.6M in Q2 2025, closing 5 positions and reducing 8 holdings. Its most notable exit was Vaxcyte, an estimated $62.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
Against the trend, Commodore Capital opened a new position in Protagonist Therapeutics worth $59.4M.
- Commodore Capital's largest Q2 2025 buy was Protagonist Therapeutics: 1,075,000 shares worth $59.4M.
- Commodore Capital added most to Xenon Pharmaceuticals in Q2 2025, an estimated $22.8M increase.
- Commodore Capital's biggest Q2 2025 reduction was Merus, cutting an estimated $44.6M.
- Commodore Capital fully exited Vaxcyte in Q2 2025, selling an estimated $62.3M.
- Commodore Capital's ten largest holdings make up 62% of its $1.42B portfolio in Q2 2025.
- Commodore Capital opened 7 new positions and closed 5 in Q2 2025.
- Commodore Capital's portfolio value rose 4.4% quarter-over-quarter to $1.42B.
Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.